ライフサイエンスコーパス: Glasgow outcome scale

1 Outcome was assessed using the Glasgow Outcome Scale.

2 good recovery or moderate disability on the Glasgow outcome scale.

3 ral basis for the clinical assessment in the Glasgow Outcome Scale.

4 ivors were assessed after 6 months using the Glasgow outcome scale.

5 Outcome was assessed at 6 months using the Glasgow Outcome Scale.

6 hs after injury was assessed by means of the Glasgow Outcome Scale.

7 el index, the modified Rankin Scale, and the Glasgow Outcome Scale.

8 , 6, and 12 months later with the use of the Glasgow Outcome Scale.

9 Oxford Handicap Scale and at 6 months by the Glasgow Outcome Scale.

10 cale of symptom severity and on the Extended Glasgow Outcome Scale.

11 Clinical outcome was assessed by Glasgow Outcome Scale.

12 ry outcomes were all-cause mortality and the Glasgow Outcome Scale.

13 y cerebral autoregulation index predictor of Glasgow Outcome Scale.

14 rapies, decompressive craniotomy, or 3-month Glasgow Outcome Scale.

15 ive to detecting changes in outcome than the Glasgow Outcome Scale.

16 er discharge survival and improved discharge Glasgow Outcome Scale.

17 for an unfavorable outcome according to the Glasgow Outcome Scale.

18 come was determined in all patients with the Glasgow outcome scale.

19 were used, most frequently the Wechsler and Glasgow Outcome Scales.

20 ad component only), 0.53 (p < .001); 6-month Glasgow Outcome Scale, -0.26 (p = .006); ICP burden (hou

21 ath, vegetative state, or severe disability (Glasgow Outcome Scale 1-3) after 6 months.

22 ortality, rupture, and unfavourable outcome (Glasgow Outcome Scale 1-4) six months after discharge an

23 tcome was measured with the 8-point Extended Glasgow Outcome Scale (1 indicates death and 8 denotes u

24 Prognostic factors for unfavorable outcome (Glasgow outcome scale, 1-4) were examined using modified

25 Rankin Scale 0-3, Barthel Index 70-100, and Glasgow Outcome Scale 4-5.

26 unfavorable global outcome according to the Glasgow Outcome Scale, a lower score on the Mini-Mental

27 ors were associated with favorable discharge Glasgow Outcome Scale: all operating room cerebral perfu

28 of adherence were associated with favorable Glasgow Outcome Scale among survivors (adjusted hazard r

29 probability of 6 months unfavorable Extended Glasgow Outcome Scale and mortality.

30 rological recovery at discharge (measured by Glasgow Outcome Scale), and length of hospital stay.

31 diac arrest using the modified Rankin Scale, Glasgow Outcome Scale, and Barthel Index.

32 gow Coma Scale (GCS), modified Rankin Scale, Glasgow Outcome Scale, and hospital and NCCU lengths of

33 st, namely Glasgow Outcome Scale or Extended Glasgow Outcome Scale, and mortality, were eligible.

34 predicted patient outcome measured with the Glasgow Outcome Scale as a continuous outcome (R = 0.82;

35 c brain injury and were classified using the Glasgow Outcome Scale as follows: moderately disabled (n

36 thalamic nuclei in patients assessed by the Glasgow Outcome Scale as moderately disabled (n = 9), se

37 tionnaire in the short term and the extended Glasgow Outcome Scale at 3 months.

38 r their effect on outcome as measured by the Glasgow Outcome Scale at 6 months after injury.

39 Outcome was assessed using the Glasgow Outcome Scale at 6 months post-injury.

40 Unfavorable outcome in Glasgow Outcome Scale at 6 months was not associated wit

41 Scores on the extended Glasgow outcome scale at 6 months were fitted to a multi

42 ociated infection rate), length of ICU stay, Glasgow Outcome Scale at 6 months, and risk factors for

43 Lower Glasgow Outcome Scale at hospital discharge and the Univ

44 s (Barthel index, modified Rankin scale, and Glasgow Outcome Scale) at days 30 and 90.

45 ng on societal participation assessed by the Glasgow Outcome Scale Extended ([GOSE] 1 to 8) and cogni

46 Functional status was assessed with Glasgow Outcome Scale Extended (GOSE) 6, 12, and 24 mont

47 ients were available for assessment with the Glasgow Outcome Scale Extended (GOSE) at 3 months and 6

48 d mortality and proportion with unfavourable Glasgow Outcome Scale Extended (GOSE) outcomes in patien

49 endpoints were 6 month mortality and 6 month Glasgow Outcome Scale Extended (GOSE) score.

50 ctional outcome at 6 months, measured by the Glasgow Outcome Scale Extended (GOSE).

51 Scale Extended = 1) and unfavorable outcome (Glasgow Outcome Scale Extended 1-4).

52 Scale Extended was dichotomized into death (Glasgow Outcome Scale Extended = 1) and unfavorable outc

53 nctional status dichotomized into favorable (Glasgow Outcome Scale Extended [GOSE] >= 5) versus poor

54 The primary outcome was the Glasgow Outcome Scale Extended at 6 months.

55 (P = 0.076) and at 1 y (P = 0.051) and with Glasgow Outcome Scale Extended at discharge (P = 0.091)

56 favorable neurological outcome, defined as a Glasgow Outcome Scale Extended score between 1 and 5, at

57 TE screening results had significantly lower Glasgow Outcome Scale Extended scores (mean [SD], 6.1 [1

58 The Glasgow Outcome Scale Extended was dichotomized into dea

59 Primary outcomes included Glasgow Outcome Scale Extended, Rivermead Cognitive Metr

60 tional outcome at 6 months as rated with the Glasgow Outcome Scale Extended, which was estimated with

61 mission) with the primary outcome of 6-month Glasgow Outcomes Scale Extended (GOS-E) and the followin

62 in the first 12 months post-injury using the Glasgow Outcome Scale - Extended (GOSE).

63 Disability was defined using Glasgow Outcome Scale-Extended <=6 at follow-up.

64 comes of all patients were assessed with the Glasgow Outcome Scale-Extended (GOS-E) at hospital disch

65 NfL levels were associated with lower 1-year Glasgow Outcome Scale-Extended (GOS-E) score (p's < 0.05

66 The primary outcome was the Glasgow Outcome Scale-Extended (GOS-E) score, which was

67 ional disability at 6 months as indicated by Glasgow Outcome Scale-Extended (GOS-E) score.

68 SF-12, Glasgow Outcome Scale-Extended (GOS-E), pain scores, and

69 fter injury, as assessed with the use of the Glasgow Outcome Scale-Extended (GOS-E).

70 outcome at 12 months was determined with the Glasgow Outcome Scale-Extended (GOS-E; levels range from

71 Ratings on the Glasgow Outcome Scale-Extended (GOSE) administered as a

72 The Glasgow Outcome Scale-Extended (GOSE) and Disability Rat

73 The main outcome was the Glasgow Outcome Scale-Extended (GOSE) at 6 months, with

74 can, and outcome assessment according to the Glasgow Outcome Scale-Extended (GOSE) at 6 months.

75 ariant allele were associated with decreased Glasgow outcome scale-extended (GOSE) score (P = 0.0231)

76 The primary outcome was a Glasgow Outcome Scale-Extended (GOSE) score of 4 or less

77 Glasgow Outcome Scale-Extended (GOSE) scores were assess

78 ter Brain Injury-Overall Scale (QOLIBRI-OS), Glasgow Outcome Scale-Extended (GOSE), and Rivermead Pos

79 were assessed at 6 months post injury on the Glasgow Outcome Scale-Extended (GOSE), the Short Form-12

80 ity was assessed 6 months post-injury by the Glasgow Outcome Scale-Extended (GOSE).

81 onal outcome at discharge, measured with the Glasgow Outcome Scale-Extended (GOSE).

82 tcome due to traumatic brain injury with the Glasgow Outcome Scale-Extended (GOSE-TBI).

83 ) or higher, as assessed with the use of the Glasgow Outcome Scale-Extended (range, 1 [death] to 8, w

84 ma Scale score to predict performance on the Glasgow Outcome Scale-Extended 10-40 months after injury

85 a 75% decreased odds of a favorable outcome (Glasgow Outcome Scale-Extended 5-8) at 6 months (adjuste

86 Brain injury-specific functional outcomes (Glasgow Outcome Scale-Extended [GOSE-TBI]), cognition (T

87 Functional independence (Glasgow Outcome Scale-Extended [GOSE] score 5 or higher)

88 rior TBI (ie, preindex TBI), and functional (Glasgow Outcome Scale-Extended [GOSE]), postconcussive (

89 , 6-month functional and disability domains (Glasgow Outcome Scale-Extended and Disability Rating Sca

90 d between studies and primarily included the Glasgow Outcome Scale-Extended and the 36-item Short For

91 disability at 6 months was assessed with the Glasgow Outcome Scale-Extended at 6 months, analyzed wit

92 able outcome as assessed by the score on the Glasgow Outcome Scale-Extended at 6 months, which we cat

93 ere functional limitations quantified by the Glasgow Outcome Scale-Extended for all injuries (GOSE-AL

94 ry imaging measures were correlated with the Glasgow Outcome Scale-Extended for Pediatrics (GOSE-Peds

95 hed patients with TBI who had good outcomes (Glasgow Outcome Scale-Extended GOS-E, 7-8) (AUC = 0.663

96 s favorable neurologic function at 6 months (Glasgow Outcome Scale-Extended score >4 [moderate disabi

97 ve, 0.04; p = 0.28) for predicting patients' Glasgow Outcome Scale-Extended score.

98 an Dysfunction Scale score, and poor 6-month Glasgow Outcome Scale-Extended score.

99 fixation remained a significant predictor of Glasgow Outcome Scale-Extended scores (beta, -0.29; p <

100 Rates of favorable improvement for the Glasgow Outcome Scale-Extended were 35.4% in the citicol

101 ) of respondents had a good recovery via the Glasgow Outcome Scale-Extended>/=7 (41.1% if patients wh

102 24 months after injury to measure function (Glasgow Outcome Scale-Extended) and return to work/study

103 Predictors of 12-month functional (Glasgow Outcome Scale-Extended) outcomes after blunt maj

104 ctured and validated measures of disability (Glasgow Outcome Scale-Extended), psychological well bein

105 tcomes included: ICU length of stay, 3-month Glasgow Outcome Scale-Extended, 3-month Disability Ratin

106 ded, 3-month Disability Rating Scale, 1-year Glasgow Outcome Scale-Extended, and 1-year Disability Ra

107 ed-up via telephone interview, including the Glasgow Outcome Scale-Extended, the 12-item short form h

108 The primary outcome was the 3-month Glasgow Outcome Scale-Extended.

109 ient characteristics, treatment, and 6-month Glasgow Outcome Scale-Extended.

110 sociated with better 6-month outcomes on the Glasgow Outcome Scale-Extended.

111 Outcome was measured at 6 months using the Glasgow Outcome Scale-Extended.

112 -month neurologic outcome as measured by the Glasgow Outcome Scale-Extended.

113 ortality and the stratified dichotomy of the Glasgow Outcome Scale-Extended.

114 oregulation index predictors of mortality or Glasgow Outcome Scale for patients with traumatic brain

115 idal neurons with a more severe score on the Glasgow Outcome Scale from all four cortical regions, wi

116 of patients with a favorable outcome on the Glasgow Outcome Scale (good recovery or moderate disabil

117 function at 3 months after injury using the Glasgow outcome scale (GOS) and the GOS-extended pediatr

118 luded neurologic outcomes assessed using the Glasgow Outcome Scale (GOS) at discharge and 6-month fol

119 The primary endpoint was the Glasgow Outcome Scale (GOS) score at 3 months after brai

120 functional outcome at 90 days, defined as a Glasgow Outcome Scale (GOS) score of 5 (range, 1 to 5, w

121 Unfavorable outcome was defined as Glasgow Outcome Scale (GOS) scores of 1-4 and Extended G

122 nd psychological outcomes was examined using Glasgow Outcome Scale (GOS) scores, measures of sustaine

123 kin scale (mRS), the Barthel index (BI), the Glasgow outcome scale (GOS), and the stroke impact scale

124 ations between TC scores and 6- and 12-month Glasgow Outcome Scale (GOS), Disability Rating Scale (DR

125 at hospital discharge was evaluated with the Glasgow Outcome Scale (GOS).

126 imary outcome was the rating on the Extended Glasgow Outcome Scale (GOS-E) (an 8-point scale, ranging

127 RI features that were predictive of Extended Glasgow Outcome Scale (GOS-E) at 3 months postinjury.

128 stic regression on the dichotomized Extended Glasgow Outcome Scale (GOS-E) at 5 years as a measure of

129 The primary outcome was Extended Glasgow Outcome Scale (GOS-E) score (range, 1-8, with lo

130 The relation of clusters to the extended Glasgow Outcome Scale (GOS-E) was investigated.

131 rimary outcome was the score on the Extended Glasgow Outcome Scale (GOS-E; range, 1 to 8, with lower

132 functional outcome (dichotomizations of the Glasgow Outcome Scale [GOS]).

133 imary outcome was the rating on the Extended Glasgow Outcome Scale (GOSE) (an 8-point scale, ranging

134 nth neurologic outcome based on the Extended Glasgow Outcome Scale (GOSE) (dichotomized as >4 or </=4

135 nfavourable) outcome of the 8 point Extended Glasgow Outcome Scale (GOSE) obtained by questionnaires

136 6-month outcome evaluated with the extended Glasgow Outcome Scale (GOSE) was assessed through a prop

137 (TBI) clinical trial endpoint, the Extended Glasgow Outcome Scale (GOSE).

138 ological outcome (assessed with the extended Glasgow Outcome Scale [GOSE]) and mortality at 6 months.

139 changes in cortical neuron population across Glasgow Outcome Scale groups between diffuse axonal inju

140 en remaining neurons usually occurred across Glasgow Outcome Scale groups.

141 heir size and nearest neighbour index across Glasgow Outcome Scale groups.

142 differences across groups classified by the Glasgow Outcome Scale in intracranial pressure, pressure

143 patterns, and poor outcomes (score of 1-2 on Glasgow Outcome Scale) in lobar intraparenchymal hemorrh

144 We used the eight-point Glasgow outcome scale obtained by postal questionnaires

145 ts versus 5 placebo patients survived with a Glasgow Outcome Scale of 4 or 5.

146 ccording to the outcomes of interest, namely Glasgow Outcome Scale or Extended Glasgow Outcome Scale,

147 le outcomes (death or modified Rankin Scale, Glasgow Outcome Scale, or World Federation of Neurosurge

148 e of the patients, assessed using either the Glasgow outcome scale (P = 0.005, n = 17) or the disabil

149 at the time of hospital discharge, using the Glasgow Outcome Scale (P<0.01).

150 001) and patient outcome (as assessed by the Glasgow Outcome Scale) (p = .05).

151 Neurocognitive recovery was assessed using Glasgow Outcome Scale (range 1-5, with 1 representing de

152 ificant differences between groups favorable Glasgow Outcome Scale (risk ratio [RR], 1.16; 95% CI, 1.

153 ciated with an increased risk of unfavorable Glasgow Outcome Scale (risk ratio, 2.46; 95% CI, 1.06-5.

154 95% CI, 1.01-3.15; I = 43%) and unfavorable Glasgow Outcome Scale (risk ratio, 2.49; 95% CI, 1.72-3.

155 dicting delayed cerebral infarctions or poor Glasgow Outcome Scale score (1-3).

156 .99-3.21; four studies) and no difference in Glasgow Outcome Scale score (mean difference, -0.45; 95%

157 Predictors for unfavorable outcome (Glasgow Outcome Scale score 1-4) were identified in a mu

158 ive with full neurocognitive recovery (i.e., Glasgow Outcome Scale score 5) in 89 patients (89%).

159 complete testing; only 3.9% of Good Outcome (Glasgow Outcome Scale score = 1) patients were untested,

160 Primary outcome measure was the Glasgow Outcome Scale score at 3 months (a score of 5 [f

161 of the stratified dichotomy of the Extended Glasgow Outcome Scale score at 6 months after injury.

162 The primary efficacy end point was the Glasgow Outcome Scale score at 6 months after the injury

163 The primary outcome was the Glasgow outcome scale score at 6 months.

164 Glasgow Outcome Scale score dichotomized as favorable (g

165 l fibrillary acidic protein serum levels and Glasgow Outcome Scale score less than or equal to 3 or E

166 le score less than or equal to 3 or Extended Glasgow Outcome Scale score less than or equal to 4 (six

167 Poor outcome, defined as Glasgow Outcome Scale Score of 3-5 at 2 months or discha

168 2 criterion was survival at 6 months with a Glasgow Outcome Scale score of 4 or 5 (group 2A) or 3 (g

169 prescription, and (3) discharge and 3-month Glasgow Outcome Scale score of 4 or 5 were ascertained.

170 Good neurologic outcome (Glasgow Outcome Scale score of 4 or 5) was determined at

171 as a modified Rankin Scale score of 0-2 or a Glasgow Outcome Scale score of 4-5.

172 r 1 more frequently exhibited full recovery (Glasgow Outcome Scale score of 5) compared with clusters

173 noid hemorrhage patients, as assessed by the Glasgow Outcome Scale score or other neurological and fu

174 The outcome was unfavorable (Glasgow outcome scale score, <5) in 24 episodes with rec

175 ents, therapies targeting edema, and 3-month Glasgow Outcome Scale score.

176 Main outcomes were discharge survival and Glasgow Outcome Scale score.

177 tested, compared with 38.6% of patients with Glasgow Outcome Scale scores of 3 and 4.

178 predict mortality and unfavorable outcomes (Glasgow Outcomes Scale scores 1-3) at 6 months.

179 found among the QOLIBRI-OS and the extended glasgow outcome scale, short-form-36, and hospital anxie

180 at admission was 7 (range 3-14), and median Glasgow Outcome Scale was 3 (range 1-5).

181 mission Glasgow Coma Scale was 6, the median Glasgow Outcome Scale was 3, and the mortality at 6 mont

182 No significant differences were found when Glasgow Outcome Scale was analyzed according to the two

183 However, in the motor cortex a more severe Glasgow Outcome Scale was associated with an increased d

184 on the Markwalder Grading Scale and Extended Glasgow Outcome Scale were generally supportive of the r

185 re, baseline Glasgow Coma Scale and 6 months Glasgow Outcome Scale were recorded.

186 onth outcome (evaluated using a dichotomized Glasgow Outcome Scale) were also introduced in multivari

187 y and functional outcome, as measured by the Glasgow Outcome Scale, were determined.